.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

CME Opportunities

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Managing Treatment Decisions for Ovarian Cancer

EP. 1: Ovarian Cancer: Talking to Patients About PARP Inhibitors

December 23rd 2017

EP. 2: Platinum Sensitivity and PARP Inhibition in Ovarian Cancer

December 23rd 2017

EP. 3: Options With Genetic Testing in Ovarian Cancer

December 23rd 2017

EP. 4: Ovarian Cancer: Making Treatment Plans Together

December 23rd 2017

EP. 5: Talking With Patients About Recurrence Risk in Ovarian Cancer

December 23rd 2017

EP. 6: Ovarian Cancer Decisions: Treatment Versus Maintenance

December 23rd 2017

EP. 7: Ovarian Cancer: Deciding Among PARP Inhibitors

December 23rd 2017

EP. 8: PARP Inhibitor Side Effect Management in Ovarian Cancer

December 23rd 2017

EP. 9: Evolving Role of PARP Inhibitors in Ovarian Cancer

December 23rd 2017

EP. 10: Unmet Needs in Ovarian Cancer

December 23rd 2017